In this Issue:
“Late diagnosis” of HCV has poor outcomes
Add PEG-IFN to entecavir in HBeAg-positive patients?
All-oral ledipasvir/sofosbuvir regimens reduce societal burden
Sofosbuvir + ribavirin effective in advanced liver disease
HCV can rapidly progress to advanced renal injury
Simeprevir + PEG-IFN/ribavirin in genotype 4 HCV
Sofosbuvir + ribavirin for 24 weeks in genotype 4 HCV
Viral factors contributing to HBsAg loss during TDF therapy
Consider HCC surveillance after HBsAg seroclearance
HLA alleles: important predictors of viral response
Please login below to download this issue (PDF)